EcoDrugPlus

Proteasome 20s Subunit Alpha 6b

Ensembl ID : ENSDLAG00005016118
Gene Symbol: PSMA6B
1 Cross references
262 Possible Orthologues:

Proteasome 20s Subunit Alpha 8

Ensembl ID : ENSDLAG00005017693
Gene Symbol: PSMA8
1 Cross references
183 Possible Orthologues:

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSDLAG00005018277
Gene Symbol: PSMB5
1 Cross references
223 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSDLAG00005011418
Gene Symbol: PSMB7
1 Cross references
215 Possible Orthologues:

Proteasome 20s Subunit Beta 9a

Ensembl ID : ENSDLAG00005031842
Gene Symbol: PSMB9A
1 Cross references
210 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4b

Ensembl ID : ENSDLAG00005013701
Gene Symbol: PSMD4B
1 Cross references
221 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1b

Ensembl ID : ENSDLAG00005016370
Gene Symbol: PSMC1B
1 Cross references
318 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSDLAG00005025389
Gene Symbol: PSMC2
1 Cross references
233 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSDLAG00005001086
Gene Symbol: PSMC4
1 Cross references
199 Possible Orthologues:

Proteasome 26s Subunit, Atpase 5

Ensembl ID : ENSDLAG00005014093
Gene Symbol: PSMC5
1 Cross references
229 Possible Orthologues:

Proteasome 26s Subunit, Atpase 6

Ensembl ID : ENSDLAG00005020310
Gene Symbol: PSMC6
1 Cross references
241 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 1

Ensembl ID : ENSDLAG00005011359
Gene Symbol: PSMD1
1 Cross references
215 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).